Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ascierto, Paolo A ^a   Simeone, Ester ^a   Sileni, Vanna C ^b   Pigozzo, Jacopo ^b   Maio, Michele ^c   Altomonte, Maresa ^c   Del Vecchio, Michele ^d   Di Guardo, Lorenza ^d   Marchetti, Paolo ^e,f   Ridolfi, Ruggero ^g   Cognetti, Francesco ^h   Testori, Alessandro ⁱ   Bernengo, Maria G ^j   Guida, Michele ^k   Marconcini, Riccardo ^l   Mandalà, Mario ^m   Cimminiello, Carolina ⁿ   Rinaldi, Gaetana ^o   Aglietta, Massimo ^p   Queirolo, Paola ^q  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Immunotherapy Unit Romagna National Cancer Institute   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j Division of Nuclear Medicine 2   (Italy)

^k NATIONAL CANCER CENTRE   (Italy)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

^p Institute of Cancer Research and Treatment Piedmont Oncology Foundation   (Italy)

^q UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Efficacy; Expanded access programme; Ipilimumab; Melanoma; Safety

Indexed keywords

B RAF KINASE; IPILIMUMAB; NRAS KINASE; PROTEIN KINASE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW APLASIA; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMPASSIONATE USE; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; HYPOTHERMIA; IMMUNE RESPONSE; ITALY; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATION RATE; NAUSEA; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETREATMENT; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901246811     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-116     Document Type: Article

References (29)

1. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010, 37:533-546. 10.1053/j.seminoncol.2010.09.015, 21074069.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
3. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
4. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day S, Chin KM, Opatt McDowell D, Cykowski L, McHenry B, Wolchok JD. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials [abstract]. J Clin Oncol 2013, 31(suppl):9053.
5. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013, 24:2174-2180. 10.1093/annonc/mdt161, 23666915.
6. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18:2039-2047. 10.1158/1078-0432.CCR-11-1823, 3319861, 22271879.
7. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011, 104:392-398. 10.1038/sj.bjc.6606030, 3049553, 21139585.
8. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013, 49:1297-1304. 10.1016/j.ejca.2012.11.019, 23290787.
9. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246. 10.1200/JCO.2010.32.4327, 21343559.
10. Spagnolo F, Queirolo P. Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 2012, 304:177-184. 10.1007/s00403-012-1223-7, 22350184.
11. Chapman PB, Hauschild A, Robert C, Larkin J, Haanen J, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan P, Dummer R, Sosman JA, Garbe C, Maio M, Nolop KB, Nelson BJ, Joe AK, Flaherty KT, McArthur GA. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol 2012, 30(suppl 15):8502.
12. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Mirakhur B, Guckert ME, Swann RS, Haney P, Goodman VL, Chapman PB. An update on BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma [abstract]. J Clin Oncol 2013, 31(suppl):9013.
13. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D, . METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114. 10.1056/NEJMoa1203421, 22663011, METRIC Study Group.
14. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256. 10.1016/S1470-2045(13)70024-X, 23414587.
15. Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:733-737. 10.1007/s00262-012-1227-3, 22382362.
16. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697. 10.1200/JCO.2012.41.6750, 22614989.
17. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymohocyte antigen-4. J Clin Oncol 2005, 23:6043-6053. 10.1200/JCO.2005.06.205, 1473965, 16087944.
18. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007, 13:6681-6688. 10.1158/1078-0432.CCR-07-0187, 2147083, 17982122.
19. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumours. Cancer Biother Radiopharm 2010, 25:601-613. 10.1089/cbr.2010.0865, 3011989, 21204754.
20. Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, de Pril V, Ibrahim R, Hoos A, O'Day S. Ipilimumab exerts disease control and survival benefits in advanced melanoma patients with and without immune-related adverse events [abstract]. J Clin Oncol 2009, 27(suppl 15):9034.
21. Queirolo P, Spagnolo F, Altomonte M, Chiarion-Sileni V, Pigozzo J, Del Vecchio M, Di Guardo L, Ridolfi R, Scoppola A, Ferrucci PF, Ferraresi V, Bernengo MG, Guida M, Marconcini R, Mandalà M, Parmiani G, Rinaldi G, Aglietta M, Simeone E, Ascierto PA. Italian cohort of the ipilimumab Expanded Access Programme: efficacy, safety and correlation with mutation status in metastatic melanoma patients [abstract]. J Clin Oncol 2013, 31(suppl):9070.
22. Di Giacomo AM, Grimaldi AM, Ascierto PA, Queirolo P, Del Vecchio M, Ridolfi R, De Rosa F, De Galitiis F, Testori A, Cognetti F, Bernengo MG, Savoia P, Guida M, Strippoli S, Galli L, Mandala M, Parmiani G, Rinaldi G, Aglietta M, Chiarion-Sileni V. Correlation between efficacy and toxicity in patients with pretreated advanced melanoma treated with the Italian cohort of the ipilimumab Expanded Access Programme [abstract]. J Clin Oncol 2013, 31(suppl):9065.
23. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014, 50:121-127. 10.1016/j.ejca.2013.09.007, 24100024.
24. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013, 24:2911-2915. 10.1093/annonc/mdt376, 24067719.
25. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumours: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
26. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013, 1291:1-13. 10.1111/nyas.12180, 3910157, 23772560.
27. Pigozzo J, Ascierto PA, Calabrò L, De Galitiis F, Ferrucci PF, Queirolo P, Bernengo MG, Aglietta M, Mandala M, Del Vecchio M. Efficacy and safety of ipilimumab reinduction therapy in patients with pretreated advanced melanoma participating in an Expanded Access Programme in Italy [abstract]. Ann Oncol 2012, 23(suppl 9):1131P.
28. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J. Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine in phase 3 study CA184-024 [abstract]. Ann Oncol 2012, 23(suppl 9):1127P.
29. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]. Eur J Cancer 2013, 49(suppl):24LBA.